In conclusion, we demonstrate that targeting JNK signaling pathway could synergistically treat Ph+ B-ALL with BCR-ABL TKI, providing a new therapeutic strategy for Ph+ B-ALL. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.